[Experts' consensus on severe acute respiratory syndrome coronavirus-2 vaccination in adult patients with hematological diseases in China (2022)].
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2022 May 14;43(5):359-364. doi: 10.3760/cma.j.issn.0253-2727.2022.05.002.
Abstract
摘要
相似文献
1
[Experts' consensus on severe acute respiratory syndrome coronavirus-2 vaccination in adult patients with hematological diseases in China (2022)].《中国成人血液病患者新型冠状病毒2型疫苗接种专家共识（2022年）》
Zhonghua Xue Ye Xue Za Zhi. 2022 May 14;43(5):359-364. doi: 10.3760/cma.j.issn.0253-2727.2022.05.002.
2
[Chinese consensus on severe acute respiratory syndrome coronavirus-2 vaccination in adult patients with hematological diseases (2023)].《成人血液病患者新型冠状病毒2型疫苗接种中国专家共识（2023年版）》
Zhonghua Xue Ye Xue Za Zhi. 2023 Jan 14;44(1):19-25. doi: 10.3760/cma.j.issn.0253-2727.2023.01.004.
3
[SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID].[成人炎症性肠病患者的新型冠状病毒2型疫苗接种：韩国炎症性肠病学会专家共识声明]
Korean J Gastroenterol. 2021 Aug 25;78(2):117-128. doi: 10.4166/kjg.2021.110.
4
Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients.西班牙血液学和输血学会关于肿瘤血液病患者 SARS-CoV-2 疫苗接种的专家共识意见。
Leuk Lymphoma. 2022 Mar;63(3):538-550. doi: 10.1080/10428194.2021.1992619. Epub 2021 Oct 20.
5
How to think about severe acute respiratory syndrome coronavirus 2 vaccination for pregnant and lactating women in China.关于中国孕妇和哺乳期妇女接种严重急性呼吸综合征冠状病毒 2 疫苗的思考。
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021 Dec 28;46(12):1386-1391. doi: 10.11817/j.issn.1672-7347.2021.210637.
6
Anti-SARS CoV-2 IgG in COVID-19 Patients with Hematological Diseases: A Single-center, Retrospective Study in Japan.血液系统疾病COVID-19患者的抗SARS-CoV-2 IgG：日本一项单中心回顾性研究
Intern Med. 2022 Jun 1;61(11):1681-1686. doi: 10.2169/internalmedicine.9209-21. Epub 2022 Mar 26.
7
[Chinese experts' consensus on diagnosis and treatment of severe and critical coronavirus disease 2019 (revised edition)].《新型冠状病毒肺炎重型、危重型病例诊疗中国专家共识（修订版）》
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 Mar;32(3):269-274. doi: 10.3760/cma.j.cn121430-20200218-00188.
8
Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.血液恶性肿瘤患者治疗对 SARS-CoV-2 疫苗接种后血清转化率的影响。
Oncologist. 2022 Apr 5;27(4):e357-e361. doi: 10.1093/oncolo/oyac032.
9
Vaccination for SARS-CoV-2 in Hematological Patients.血液系统疾病患者的 SARS-CoV-2 疫苗接种。
Acta Haematol. 2022;145(3):257-266. doi: 10.1159/000523753. Epub 2022 Feb 25.
10
Diagnosis, treatment and prevention of severe acute respiratory syndrome coronavirus 2 infection in children: experts' consensus statement updated for the Omicron variant.儿童严重急性呼吸综合征冠状病毒2感染的诊断、治疗及预防：针对奥密克戎变异株的专家共识声明更新版
World J Pediatr. 2024 Mar;20(3):272-286. doi: 10.1007/s12519-023-00745-3. Epub 2023 Sep 7.
引用本文的文献
1
[Allogeneic hematopoietic stem cell transplantation during the normalization stage of COVID-19 management].[新型冠状病毒肺炎管理正常化阶段的异基因造血干细胞移植]
Zhonghua Xue Ye Xue Za Zhi. 2024 Nov 14;45(11):977-981. doi: 10.3760/cma.j.cn121090-20240817-00308.
2
Management of chronic myelogenous leukemia with COVID-19 and hepatitis B.新冠病毒肺炎合并乙型肝炎的慢性髓性白血病的管理
Front Oncol. 2023 Aug 3;13:1217023. doi: 10.3389/fonc.2023.1217023. eCollection 2023.
本文引用的文献
1
A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2.第三剂灭活疫苗可增强针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的回忆反应的效力、广度和持续时间。
Protein Cell. 2024 Dec 2;15(12):930-937. doi: 10.1093/procel/pwae033.
2
COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research.COVID-19 突破性感染、血液病患者完全接种疫苗后的住院和死亡：呼吁继续采取缓解措施和加强研究。
Blood Rev. 2022 Jul;54:100931. doi: 10.1016/j.blre.2022.100931. Epub 2022 Jan 31.
3
Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant.延长加强针间隔时间对奥密克戎变种中和作用的影响。
N Engl J Med. 2022 Mar 3;386(9):894-896. doi: 10.1056/NEJMc2119426. Epub 2022 Jan 26.
4
Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors.接受酪氨酸激酶抑制剂治疗的慢性髓性白血病患者在接种第二剂抗SARS-CoV-2疫苗后的持久体液免疫反应。
Br J Haematol. 2022 Apr;197(1):e1-e4. doi: 10.1111/bjh.18001. Epub 2021 Dec 19.
5
Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma.抗CD38疗法会损害多发性骨髓瘤患者针对新冠病毒α和δ变体的疫苗反应。
Blood. 2022 Feb 10;139(6):942-946. doi: 10.1182/blood.2021013714.
6
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.科兴新冠疫苗加强免疫的免疫原性和安全性，以及两剂接种程序的免疫持久性：两项单中心、双盲、随机、安慰剂对照的 2 期临床试验的中期结果。
Lancet Infect Dis. 2022 Apr;22(4):483-495. doi: 10.1016/S1473-3099(21)00681-2. Epub 2021 Dec 8.
7
Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study.BNT162b2 mRNA COVID-19 疫苗在慢性淋巴细胞白血病患者中的疗效：血清学和细胞研究。
Chemotherapy. 2022;67(2):91-95. doi: 10.1159/000521229. Epub 2021 Dec 6.
8
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.三剂 BNT162b2 mRNA COVID-19 疫苗在标准两剂接种失败的 CLL 患者中的疗效。
Blood. 2022 Feb 3;139(5):678-685. doi: 10.1182/blood.2021014085.
9
Patients presenting high fever with lymphadenopathy after COVID-19 vaccination were diagnosed with hemophagocytic lymphohistiocytosis.接种 COVID-19 疫苗后出现高热伴淋巴结病的患者被诊断为噬血细胞性淋巴组织细胞增生症。
Infect Dis (Lond). 2022 Apr;54(4):303-307. doi: 10.1080/23744235.2021.2010801. Epub 2021 Dec 2.
10
Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium.癌症和 COVID-19 患者的延长生命治疗限制和结果：荷兰肿瘤 COVID-19 联盟的最新信息。
Eur J Cancer. 2022 Jan;160:261-272. doi: 10.1016/j.ejca.2021.10.009. Epub 2021 Oct 25.
Zotero 插件